IFNB1 and myocarditis: Notably, the phase II BICC clinical trial examined the impact of IFN-β therapy on viral clearance in patients with inflammatory cardiomyopathy and persistent myocardial viral infection caused by adenovirus, enterovirus, or B19V; patients with myocarditis positive for enterovirus or adenovirus, confirmed via endomyocardial biopsy, experienced viral clearance following IFN-β treatment.